N/A
Manufactured by Sandoz Inc
28,834 FDA adverse event reports analyzed
Last updated: 2026-04-14
BRIMONIDINE TARTRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Sandoz Inc. The most commonly reported adverse reactions for BRIMONIDINE TARTRATE include TREATMENT FAILURE, DRUG INEFFECTIVE, ERYTHEMA, EYE IRRITATION, OCULAR HYPERAEMIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for BRIMONIDINE TARTRATE.
Out of 17,080 classified reports for BRIMONIDINE TARTRATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 28,834 FDA FAERS reports that mention BRIMONIDINE TARTRATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TREATMENT FAILURE, DRUG INEFFECTIVE, ERYTHEMA, EYE IRRITATION, OCULAR HYPERAEMIA, EYE PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Sandoz Inc in connection with BRIMONIDINE TARTRATE. Always verify the specific product and NDC with your pharmacist.